リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

大学・研究所にある論文を検索できる 「Therapeutic Drug Monitoring of Antibody Drugs」の論文概要。リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。
リケラボ

コピーが完了しました

URLをコピーしました

論文の公開元へ論文の公開元へ
書き出し

Therapeutic Drug Monitoring of Antibody Drugs

Yonezawa, Atsushi 京都大学 DOI:10.1248/bpb.b22-00006

2022.07.01

概要

In recent years, many antibody drugs that play an important role in the pharmacotherapy of several diseases have been developed. Antibody drugs exhibit immunogenicity in vivo leading to the development of antibodies against the antibody drug (anti-drug antibody). Nonetheless, other factors also affect the pharmacokinetics of antibody drugs. Recently, therapeutic drug monitoring (TDM) of infliximab was introduced for personalized medicine. However, the usefulness of TDM in antibody therapy remains unclear. In addition to intervention studies, real-world data analysis is important. Unlike small-molecule drugs, antibody drugs do not have a uniform molecular weight; therefore, using the conventional analysis methods, it is impossible to determine the true pharmacokinetic outcomes of these agents. To analyze structural changes of antibody drugs in the body, new technologies are necessary. In the future, along with the development of new drugs, the establishment of novel analytical methods is essential to facilitate the promotion of personalized medicine.

論文の公開元へ

関連論文

関連論文をもっと見る

参考文献

1) Walsh G, Jefferis R. Post-translational modifications in the context of therapeutic proteins. Nat. Biotechnol., 24, 1241–1252 (2006).

2) Hamuro LL, Kishnani NS. Metabolism of biologics: biotherapeutic proteins. Bioanalysis, 4, 189–195 (2012).

3) Miller RA, Maloney DG, Warnke R, Levy R. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N. Engl. J. Med., 306, 517–522 (1982).

4) Levy R. A brief personal history of cancer immunotherapy at Stanford: if these walls could talk…. Immunol. Res., 58, 277–281 (2014).

5) Mössner E, Brünker P, Moser S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cellmediated B-cell cytotoxicity. Blood, 115, 4393–4402 (2010).

6) Dostalek M, Gardner I, Gurbaxani BM, Rose RH, Chetty M. Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies. Clin. Pharmacokinet., 52, 83–124 (2013).

7) Garg A, Balthasar JP. Physiologically-based pharmacokinetic (PBPK) model to predict igg tissue kinetics in wild-type and fcrnknockout mice. J. Pharmacokinet. Pharmacodyn., 34, 687–709 (2007).

8) Baert F, Noman M, Vermeire S, Van Assche G, D’ Haens G, Carbonez A, Rutgeerts P. Influence of immunogenicity on the longterm efficacy of infliximab in Crohn’s disease. N. Engl. J. Med., 348, 601–608 (2003).

9) Kalden JR, Schulze-Koops H. Immunogenicity and loss of response to TNF inhibitors: implications for rheumatoid arthritis treatment. Nat. Rev. Rheumatol., 13, 707–718 (2017).

10) Neubert H, Alley SC, Lee A, et al. 2020 White paper on recent issues in bioanalysis: BMV of hybrid assays, acoustic MS, HRMS, data integrity, endogenous compounds, microsampling and microbiome. Bioanalysis, 13, 203–238 (2021).

11) Iwamoto N, Shimada T, Umino Y, Aoki C, Aoki Y, Sato TA, Hamada A, Nakagama H. Selective detection of complementaritydetermining regions of monoclonal antibody by limiting protease access to the substrate: nano-surface and molecular-orientation limited proteolysis. Analyst, 139, 576–580 (2014).

12) Iwamoto N, Takanashi M, Yokoyama K, Yonezawa A, Denda M, Hashimoto M, Tanaka M, Ito H, Matsuura M, Yamamoto S, Honzawa Y, Matsubara K, Shimada T. Multiplexed monitoring of therapeutic antibodies for inflammatory diseases using Fab-selective proteolysis nsmol coupled with LC-MS. J. Immunol. Methods, 472, 44–54 (2019).

13) Strand V, Balsa A, Al-Saleh J, Barile-Fabris L, Horiuchi T, Takeuchi T, Lula S, Hawes C, Kola B, Marshall L. Immunogenicity of biologics in chronic inflammatory diseases: a systematic review. BioDrugs, 31, 299–316 (2017).

14) Takeuchi T, Miyasaka N, Tatsuki Y, Yano T, Yoshinari T, Abe T, Koike T. Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis. Ann. Rheum. Dis., 70, 1208–1215 (2011).

15) Takeuchi T, Miyasaka N, Inoue K, Abe T, Koike T. Impact of trough serum level on radiographic and clinical response to infliximab plus methotrexate in patients with rheumatoid arthritis: results from the RISING study. Mod. Rheumatol., 19, 478–487 (2009).

16) Nakae K, Masui S, Yonezawa A, et al. Potential application of measuring serum infliximab levels in rheumatoid arthritis management: a retrospective study based on KURAMA cohort data. PLOS ONE, 16, e0258601 (2021).

17) Otani Y, Yonezawa A, Tsuda M, Imai S, Ikemi Y, Nakagawa S, Omura T, Nakagawa T, Yano I, Matsubara K. Time-dependent structural alteration of rituximab analyzed by LC/TOF-MS after a systemic administration to rats. PLOS ONE, 12, e0169588 (2017).

18) Yonezawa A, Otani Y, Kitano T, Mori M, Masui S, Isomoto Y, Tsuda M, Imai S, Ikemi Y, Denda M, Sato Y, Nakagawa S, Omura T, Nakagawa T, Yano I, Hayakari M, Takaori-Kondo A, Matsubara K. Concentration and glycoform of rituximab in plasma of patients with B cell non-Hodgkin’s lymphoma. Pharm. Res., 36, 82 (2019).

参考文献をもっと見る